Programmed death-ligand 1 and CKLF-like MARVEL transmembrane domain-containing protein 6 complex (PD-L1/CMTM6 complex)

The PD-L1/CMTM6 complex refers to the physical association of PD-L1 (programmed death-ligand 1), an immune checkpoint protein, with CMTM6 (CKLF-like MARVEL transmembrane domain-containing protein 6), a transmembrane protein that stabilizes PD-L1 on the surface of tumor and antigen-presenting cells[1][4][5][8]. This stabilization prevents PD-L1 from intracellular degradation (lysosomal, proteasomal, and ubiquitin-mediated routes), thereby maintaining high PD-L1 density at the membrane and promoting immune evasion in cancers[1][3][4][5][8]. CMTM6 does not affect PD-L1 transcription but instead physically interacts and co-localizes with PD-L1, extending its half-life and enhancing PD-1/PD-L1 signaling, which suppresses cytotoxic T cell activity[1][3][4][5]. Therapeutic interventions targeting this complex (either PD-L1 or CMTM6) are under active investigation, with checkpoint inhibitors already in clinical use and early-stage development of agents against CMTM6 itself[3][5]. The complex has emerged as a promising marker and therapeutic target, especially in tumors resistant to conventional therapies.

Other names

PD-L1-CMTM6 complexPD-L1 and CMTM6Programmed death-ligand 1-CMTM6 complexCD274-CMTM6 complex (CD274 is another name for PD-L1)

Blockade of PD-1/PD-L1 interaction to restore T cell activity[3][5] Destabilization or downregulation of PD-L1 (by disrupting CMTM6 binding or CMTM6 levels)[2][3] Interference with protein-protein stabilization at cell surface[1][3][4] Targeted antibody or nanobody binding to CMTM6 (preclinical)[3]